Oviva adds Kinnevik in €200m Series D and secondary transaction
Kinnevik leads a transaction combining new equity and shareholder liquidity as Oviva expands reimbursed treatment for chronic conditions.
Oviva has brought in Kinnevik as lead investor in a €200 million transaction that combines Series D financing with purchases of existing shares. The primary capital allocation has not been separately disclosed in the issuer’s announcement.
Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen AG, Norrsken VC and existing investor Sofina also participated. Kinnevik announced a $100 million investment as part of the transaction.
The new financing will support Oviva’s expansion into additional chronic conditions and development of AI tools for patients and clinicians. Its care model combines digital treatment with clinical support through reimbursed healthcare programmes in Germany, the UK and Switzerland.
Use of funds
Expand reimbursed care for chronic conditions
Develop clinical AI tools